CD34 and breast cancer: While studying the role of miR-142 deficit in CML evolution16, we observed that miR-142 was significantly decreased not only in CD34+CD38- blasts16 but also in T cells from BC CML patients compared with CP CML patients (Supplementary Fig. 1a).